Alligator Appoints Theradex as Study CRO

Alligator Bioscience has appointed Theradex Oncology as the CRO for the planned phase I study of ATOR-1015 for the treatment of metastatic cancer. The study is expected to commence in the second half of 2018.

The upcoming clinical phase I study is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark.

“Engaging Theradex is a key step towards starting our clinical phase I study with ATOR-1015 later this year”, said Per Norlén, chief executive officer of Alligator Bioscience. “We have worked previously with Theradex on the ADC-1013 clinical phase I trial and, based on their robust delivery and extensive expertise in clinical oncology research, we are confident in their ability to assist us in executing high-quality studies and we look forward to continuing our successful collaboration”.

ATOR-1015 is a first-in-class bispecific antibody that targets CTLA-4 and OX40 and was created with Alligator’s unique bispecific technology. Production of clinical trial material has already been completed and the final clinical trial authorization (“CTA”) enabling activities required for study initiation will be completed in H1 2018.